Drugs.com - Monthly Update January 2026
In our latest episode, we cover the latest approval of Darzalex Faspro for multiple myeloma, age-related near vision loss, and a rare genetic disorder affecting children. We also discuss an extension to the use of Nexplanon, a long-acting birth control, and a simpler transition for those moving from injected to inhaled insulin.
- Darzalex Faspro (daratumumab and hyaluronidase-fihj) a new approval for use in combination with standard treatments for adults with newly diagnosed multiple myeloma.
- Yuvezzi (carbachol and brimonidine tartrate), a novel combination eye drop for presbyopia.
- Zycubo (copper histidinate), the first treatment for Menkes disease in children.
- Nexplanon (etonogestrel), a birth control implant with an extension of use for up to five years.
- Afrezza (insulin human), an inhaled insulin, with updated dosing guidance.
Chapters
- (00:00) - Intro
- (00:21) - Overview
- (00:47) - Darzalex
- (02:13) - Yuvezzi
- (03:06) - Zycubo
- (03:50) - Nexplanon
- (04:35) - Afrezza
- (05:09) - Outro
Follow Drugs.com:
- X, Facebook, Youtube
- Signup to our newsletters
- Download the app
